Brigatinib Approved in Europe for ALK+ NSCLC

November 27, 2018 – The European Commission has approved brigatinib for the treatment of adult patients with ALK-positive non–small cell lung cancer (NSCLC) who were previously treated with crizotinib, according to Takeda Pharmaceutical Company, the developer of the ALK inhibitor. The approval follows a positive opinion granted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in September … (leggi tutto)